R1	Has_value Arg1:T1 Arg2:T2	
R2	Has_temporal Arg1:T1 Arg2:T3	
R3	Has_qualifier Arg1:T5 Arg2:T4	
R4	Has_qualifier Arg1:T5 Arg2:T6	
*	OR T8 T7
R5	Has_context Arg1:T5 Arg2:T8	
R7	Has_multiplier Arg1:T11 Arg2:T10	
R6	Has_temporal Arg1:T11 Arg2:T12	
*	OR T19 T18
R8	Has_temporal Arg1:T16 Arg2:T19	
*	OR T15 T16
R9	Has_multiplier Arg1:T15 Arg2:T13	
R10	AND Arg1:T15 Arg2:T17	
R11	Has_temporal Arg1:T15 Arg2:T14	
R12	Has_multiplier Arg1:T25 Arg2:T24	
R13	Has_negation Arg1:T24 Arg2:T23	
R14	AND Arg1:T15 Arg2:T25	
R15	AND Arg1:T5 Arg2:T11	
T1	Person 0 3	Age
T2	Value 4 15	>/=18 years
T3	Temporal 16 28	at screening
T4	Qualifier 44 59	relapsing forms
T5	Condition 63 87	multiple sclerosis (RMS)
T6	Qualifier 93 107	active disease
T7	Observation 131 147	imaging features
T8	Observation 119 127;139 147	clinical features
T10	Multiplier 153 165;183 204	at least one over a 6-month period
T11	Condition 166 182	clinical relapse
T12	Temporal 205 223	prior to screening
T13	Multiplier 237 249;379 401	at least one over a 3 months period
T14	Temporal 402 420	prior to screening
T15	Condition 250 280	T1 gadolinium-enhancing lesion
T16	Condition 305 314	T2 lesion
T17	Procedure 330 368	brain Magnetic Resonance Imaging (MRI)
T18	Qualifier 295 304	enlarging
T19	Temporal 284 287	new
T23	Negation 426 428	no
T24	Multiplier 429 438	change of
T25	Procedure 439 475	Disease-Modifying Treatment(s) (DMT)
T26	Non-representable 476 546	compared to a previous MRI performed within 24 months before screening
T28	Pregnancy_considerations 548 726	For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 12 months after the last dose of ocrelizumab
T29	Observation 751 785	beneficiary of healthcare coverage
